Elixir Medical’s DynamX® Bioadaptor Shows Lower Event Rates Than Drug-Eluting Stent
During the EuroPCR 2026 conference, Elixir Medical presented four-year results from the BIOADAPTOR Randomized Controlled Trial, showing that the DynamX® Coronary Bioadaptor System has significantly lower target lesion failure (TLF) rates and cardiovascular death compared to the Resolute Onyx drug-eluting stent (DES). The trial involved 445 patients and highlighted that DynamX® maintains low adverse event rates while restoring normal artery function.
EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death
EuroPCR 2026: Elixir Medical’s DynamX® Bioadaptor Demonstrates Significantly Lower Event Rates Than Drug-Eluting Stent in Long-Term Follow-Up, Including Reduction in Cardiovascular Death